Sertraline Hydrochloride API is a pharmaceutical active ingredient belonging to the selective serotonin reuptake inhibitor (SSRI) class of antidepressants. It is the hydrochloride salt of sertraline and is widely recognized as an important pharmaceutical compound used in the development and manufacture of medicines for several psychiatric disorders. Sertraline Hydrochloride is identified by CAS Number 79559-97-0, with the molecular formula C₁₇H₁₈Cl₃N and a molecular weight of approximately 342.69 g/mol.
Sertraline works primarily by selectively inhibiting the neuronal reuptake of serotonin. By reducing serotonin reuptake, it increases the availability of serotonin within the central nervous system. This pharmacological mechanism is responsible for its therapeutic activity and distinguishes sertraline from many other antidepressant classes. Sertraline Hydrochloride is therefore an important SSRI pharmaceutical API for pharmaceutical formulation and drug manufacturing.
Sertraline Hydrochloride is used in medicinal products indicated for a range of psychiatric conditions. These include major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and social anxiety disorder. Regulatory labeling also identifies additional indications depending on the specific approved product and market.
Because of its established therapeutic use, Sertraline Hydrochloride remains an important active ingredient for pharmaceutical manufacturers producing tablets, capsules and other oral dosage formulations.
Sertraline Hydrochloride is a white crystalline powder. FDA labeling describes it as slightly soluble in water and isopropyl alcohol and sparingly soluble in ethanol. The hydrochloride salt has a molecular weight of approximately 342.7 g/mol.
The pharmaceutical API contains a defined stereochemical configuration. The approved sertraline active ingredient corresponds to the (1S,4S) configuration, commonly described in regulatory labeling as the (1S-cis) form. Control of stereochemical purity is therefore an important component of Sertraline Hydrochloride API quality control.
Quality control is particularly important for Sertraline Hydrochloride because the API has defined stereochemical requirements and several pharmacopeial impurity controls.
The USP monograph specifies that Sertraline Hydrochloride contains 97.0% to 102.0% of sertraline hydrochloride, calculated on an anhydrous basis. USP also specifies residue on ignition NMT 0.3%, heavy metals 30 ppm, and water NMT 0.50%.
USP further includes specific chromatographic controls for related substances, including the (R,R)-sertraline hydrochloride stereoisomer and several specified impurities. The USP monograph identifies an acceptance limit of NMT 1.5% for (R,R)-sertraline hydrochloride and provides controls for several other individual and total impurities.
These controls demonstrate the importance of validated chromatographic methods and stereochemical impurity monitoring when manufacturing pharmaceutical-grade Sertraline Hydrochloride.
A comprehensive analytical testing program for Sertraline Hydrochloride can include infrared identification, chromatographic identification, HPLC assay, related-substance testing, stereochemical impurity determination, water determination, residue-on-ignition testing and elemental impurity assessment.
The USP monograph uses chromatographic methods for assay and for the determination of the (R,R)-sertraline hydrochloride impurity. Water is determined using the USP water-determination procedure, rather than a generic loss-on-drying test.
This distinction is important when preparing pharmaceutical API specifications. For Sertraline Hydrochloride, the CMS field Water Content should therefore contain the USP value of NMT 0.50%, while Loss on Drying should not be populated with an invented value.
A reliable Sertraline Hydrochloride API Manufacturer in India should maintain appropriate controls over raw materials, chemical processing, purification, crystallization, drying and final packaging.
Particular attention should be given to stereochemical purity and related substances. The manufacturing process should consistently produce the required cis stereochemical form while controlling racemic and other process-related impurities.
Pharmaceutical API manufacturing should also include validated analytical procedures, appropriate batch traceability and a documented quality system. Analytical documentation can include Certificate of Analysis, product specifications, chromatographic data, impurity profiles, residual-solvent information and stability data, according to the applicable customer and regulatory requirements.
Sertraline Hydrochloride should be maintained in suitable pharmaceutical packaging that protects the material from environmental exposure. The USP monograph specifies preservation in tight, light-resistant containers at a temperature not exceeding 40°C.
Packaging should therefore provide appropriate protection against moisture, light and other environmental conditions that could affect API quality during transportation and storage.
Sertraline Hydrochloride Bulk API is relevant to pharmaceutical formulation development, generic drug manufacturing, analytical research and commercial production of sertraline-containing medicinal products.
For pharmaceutical manufacturers, important quality attributes include assay, water content, residue on ignition, heavy-metal control, related substances and stereochemical purity. Maintaining consistent quality across production batches is essential for downstream formulation and regulatory compliance.
Sertraline Hydrochloride is an established SSRI pharmaceutical ingredient with broad therapeutic applications and well-defined pharmacopoeial quality requirements. Its USP monograph provides measurable requirements for assay, impurities, water, residue on ignition and heavy metals, allowing pharmaceutical manufacturers to establish a clearly defined quality-control framework.
A dependable Sertraline Hydrochloride API Manufacturer in India should therefore emphasize pharmaceutical-grade quality, validated analytical testing, stereochemical control, batch consistency, appropriate packaging and comprehensive technical documentation.
Sertraline Hydrochloride, CAS 79559-97-0, continues to be an important pharmaceutical active ingredient for the development and manufacture of SSRI-based medicines.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 97.0% – 102.0% |
| Residue on Ignition | NMT 0.3% |
| Heavy Metals | NMT 30 ppm |
| Water Content | NMT 0.50% |